Back to News
Market Impact: 0.2
Alentis and PinotBio Announce Collaboration to Develop Next-Generation ADCs Targeting claudin-1
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Alentis and PinotBio agreed to discover and develop next-generation antibody-drug conjugates targeting claudin-1 for oncology. The announcement provides no financial terms, development milestones, or expected timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Why is Samsung Electronics stock plunging today?
- SK Hynix plunges 8% amid Asia tech rout as Fed rate hike fears, AI funding worries mount
- Elon Musk says Trump is 'ultimately' responsible for any curbs on Ukraine's Starshield systems
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Rocket Lab stock tumbling today?